Gene Therapy for HER-Positive Cancer (SENTRY-HER2)
Gene Therapy for HER-Positive Cancer (SENTRY-HER2)
Recruiting · NCT07192432 · Registry updated 2026-07-28Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Gene Therapy for HER-Positive Cancer (SENTRY-HER2) | HER2 Expressing Solid Tumors | Recruiting | Phase 1 / Phase 2 | 2026-07-28 | NCT07192432 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Vironexis Biotherapeutics Inc. | 2 |
11 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Cleveland Clinic | Cleveland | United States | 558 |
| Hackensack Medical Center | Hackensack | United States | 9 |
| Mayo Clinic | Rochester | United States | 1 |
| Mayo Clinic | Jacksonville | United States | 122 |
| Memorial Sloan Kettering Cancer Center | New York | United States | 1000 |
| SCRI Denver DDU at HealthOne | Denver | United States | 1 |
| Scri Oncology Partners | Nashville | United States | 156 |
| Thomas Jefferson University, Sidney Kimmel Cancer Center | Philadelphia | United States | 14 |
| UT MD Anderson Cancer Center | Houston | United States | 204 |
| Valkyrie Clinical Trials | Los Angeles | United States | 47 |
| VCU Massey CTO Phase I Solid Team | Richmond | United States | 1 |